Humacyte, Inc. Appoints Two Directors to Strengthen Board Oversight

What Happened Humacyte, Inc. announced that on September 22, 2026 it appointed Scott Coward and Paul Kuznik to its Board of Directors. Mr. Coward will serve as a Class I director with a term expiring in 2028 and has been named to the Audit Committee. Mr. Kuznik will serve as a Class II director with a term expiring in 2029 and has been named to the Commercial Committee. The company furnished a press release about the appointments on September 28, 2026 (Exhibit 99.1 to the 8‑K).

Key Details

• Appointment dates and terms: both appointed Sept. 22, 2026; Coward term expires 2028, Kuznik term expires 2029.
• Committee assignments: Coward → Audit Committee; Kuznik → Commercial Committee.
• Director pay: each will receive a $50,000 annual cash retainer (prorated for 2026), $5,000/year for committee service (prorated for 2026), and an option to purchase 125,000 shares of common stock.
• Background: Coward is an attorney at K&L Gates (since July 2026) and former Executive VP/Chief Legal Officer of Exact Sciences; Kuznik is a medical-technology executive with leadership roles at Bolton Medical and Terumo Aortic and is a West Point graduate.

Why It Matters New board members bring governance, legal/M&A, commercialization and medical-device experience that can affect corporate oversight and strategy execution. Coward’s audit committee placement adds legal and public‑company governance experience relevant to financial oversight; Kuznik’s commercial and operational background supports commercialization and manufacturing oversight. Compensation for each director includes 125,000 stock options, which investors should note as potential equity dilution when assessing shareholder impact. The filing states there are no related-party arrangements or material transactions requiring further disclosure.